Tanigawa K., Itoh Y., Kobayashi Y. Improvement of QOL and Immunological Function With Lentinula Edodes Mycelia in Patients Undergoing Cancer Immunotherapy: An Open Pilot Study. Alternative Therapies in Health and Medicine. 2016;22(4):36–42.
Rationale
Whether a mushroom preparation can support modern cellular immunotherapy — dendritic-cell vaccines, activated T-cells — is a different and harder question than adjuvant-to-chemotherapy. This pilot used a sequential design to see it.
Methods
An open-label pilot: 10 cancer patients on immunotherapy (dendritic-cell vaccine or CD3-activated T-lymphocyte therapy). Design: 4 weeks of immunotherapy alone, then 4 weeks of immunotherapy + oral LEM 1800 mg/day. Quality of life and IFN-γ were tracked.
Results
During immunotherapy alone, quality of life worsened; after LEM was added, QOL improved significantly and IFN-γ showed an upward trend.
Conclusions
The first clinical hint that LEM can complement adaptive immunotherapy — improving tolerability of the treatment course.
Worth noting
The sequential within-patient design (immunotherapy → immunotherapy+LEM) is clever for a pilot — each patient is their own comparator — but open-label and n=10 keep it at hypothesis level. The IFN-γ trend fits the intended Th1 mechanism. Worth a controlled follow-up, which has not materialized at scale.